Gilead officer sells 3,000 shares under trading plan
Gilead Sciences executive Johanna Mercier reported open-market sales of 3,000 shares of Gilead common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Gilead Sciences executive Johanna Mercier reported open-market sales of 3,000 shares of Gilead common stock. The transactions occurred on June 15, 2026 at prices ranging from $122.79 to $125.40 per share, as described in the footnotes.
The filing states that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. After the transactions, Mercier directly holds 124,234 shares of Gilead common stock, according to the reported post-transaction balance.
Insider Trade Summary 10b5-1
Net Seller: 3,000 shares
Net Sell
3 txns
Insider
Mercier Johanna
Role
Chief Comm & Corp Aff Officer
Sold
3,000 shs ($372K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,480 | $123.4166 | $183K |
| Sale | Common Stock | 1,070 | $123.9958 | $133K |
| Sale | Common Stock | 450 | $125.40 | $56K |
Holdings After Transaction:
Common Stock — 124,234 shares (Direct)
Footnotes (3)
- F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
- F2. Sale prices for the transactions reported range from $122.79 to $123.785. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F3. Sale prices for the transactions reported range from $123.81 to $124.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Key Figures
Shares sold: 3,000 shares
Highest reported line-item sale price: $125.40 per share
Reported sale price ranges: $122.79–$124.23 per share
+2 more
5 metrics
Shares sold
3,000 shares
Total common shares sold on June 15, 2026
Highest reported line-item sale price
$125.40 per share
One of the open-market sale transactions on June 15, 2026
Reported sale price ranges
$122.79–$124.23 per share
Price ranges described in footnotes F2 and F3
Shares held after transactions
124,234 shares
Direct common stock ownership after June 15, 2026 sales
10b5-1 plan adoption date
February 20, 2025
Date the pre-arranged trading plan was adopted
Key Terms
Rule 10b5-1 trading plan, open-market sale, Form 4, non-derivative, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
non-derivative financial
"transaction_type": "non-derivative""
Common Stock financial
"security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Does this Gilead (GILD) Form 4 show a pre-planned Rule 10b5-1 sale?
Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Such plans pre-schedule trades, indicating these sales were arranged in advance rather than timed in response to short-term market events.
What role does Johanna Mercier have at Gilead (GILD) in this Form 4?
Johanna Mercier is listed as an officer of Gilead Sciences, serving as Chief Commercial & Corporate Affairs Officer. The Form 4 identifies her insider status, which requires reporting transactions like these sales of Gilead common stock to the SEC.
What type of transaction is reported for Gilead (GILD) in this Form 4?
The filing reports open-market sales of common stock, coded as “S” transactions. Each entry is classified as a non-derivative sale, with the transaction description indicating sales in the open market or private transactions and no derivative exercises reported.
AI-generated analysis. How Rhea-AI works. Not financial advice.
